Monday, April 09, 2018 1:07:49 PM
https://globenewswire.com/news-release/2018/04/09/1466879/0/en/TRACON-Pharmaceuticals-Announces-Closing-of-Previously-Announced-Private-Placement-and-Appointment-of-Ted-Wang-Ph-D-of-Puissance-Capital-Management-to-Board-of-Directors.html
Puissance recently filed a Form 3
https://www.sec.gov/Archives/edgar/data/1394319/000173343918000004/xslF345X02/primary_doc.xml
Ted Wang:
Mr. Wang is CIO of Puissance Capital and brings with him 18 years of global equities trading and investing experience. Mr. Wang was a Partner of Goldman, Sachs & Co and during his 18-year tenure at the firm he held many leadership positions, mostly recently as Co-Head of US Equities Trading and Global Co-Head of One Delta Trading and a member of the Goldman Sachs Risk Committee. At his retirement, he was the most senior Chinese partner at the firm and was deeply involved in the firm’s strategy in China, where he developed extensive relationships with government officials, regulators, corporate and investing clients. Mr. Wang has distinguished himself throughout his career at Goldman Sachs for successfully navigating many volatile markets. He also gained extensive operational expertise while managing various Goldman trading businesses globally, including operations, technology, credit and legal and compliance. Mr. Wang joined Goldman Sachs in 1996, was named Managing Director in 2002, and Partner in 2006. Prior to joining Goldman, Mr. Wang co-founded Xeotron Corp., a company specializing in DNA biochips in Texas. He holds a PhD in Physics from the University of Minnesota, an MBA from the University of Texas, Austin, and a BS from Fudan University, China. He is co-chair of the board of trustees of the Museum of Chinese in America, a trustee of the China Institute, the Dunhuang Foundation, the Spence School, and a member of Committee of 100.
Recent TCON News
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/07/2024 10:03:57 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2024 10:00:35 PM
- TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024 • GlobeNewswire Inc. • 02/28/2024 09:02:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:31:59 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/09/2024 09:05:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 10:00:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2023 10:00:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 01:05:40 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:00:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2023 09:00:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 12:10:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:11:15 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 09:01:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:12:31 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/07/2023 09:02:56 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 07/25/2023 09:19:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2023 12:08:13 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM